Sapien Valve Reimbursement Begins Taking Shape, But Key Questions Remain

Edwards Lifescience’s proactive reimbursement strategy for its market-pending Sapien transcatheter aortic valve appears to be progressing as planned, but questions remain about how Medicare coverage policies could ultimately affect adoption of the closely- watched technology.

More from Archive

More from Medtech Insight